Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease

Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau

(2020) Edward N Wilson et al.   BRAIN

Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use

(2020) Cristina d’Abramo et al.   Journal of Personalized Medicine

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

(2019) Isabelle Bos et al.   Alzheimers & Dementia

Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles

(2019) Richard M. Meade et al.   Molecular Neurodegeneration

Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease

(2019) Brit Mollenhauer et al.   MOVEMENT DISORDERS

Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology

(2019) Fares Bassil et al.   NEURON

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative

(2018) Dallas P. Veitch et al.   Alzheimers & Dementia

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

(2017) Daniela Bertens et al.   Alzheimers Research & Therapy

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease

(2017) Chelsea Caspell-Garcia et al.   PLoS One

Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder

(2016) L.M. Chahine et al.   PARKINSONISM & RELATED DISORDERS

Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease

(2016) Xiao-Yan Qin et al.   JAMA Neurology

Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay

(2015) Wendy E. Heywood et al.   Molecular Neurodegeneration

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies

(2015) Malin Wennström et al.   PLoS One

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

(2013) David J. Irwin et al.   NATURE REVIEWS NEUROSCIENCE

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

(2012) Irene Litvan et al.   MOVEMENT DISORDERS

APOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies

(2012) Debby Tsuang et al.   JAMA Neurology

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY